leisure time -WSS

leisure time

author：comprehensive 2025-09-02 22:02:16 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

WSS

People with substance use disorder deserve online privacy

Patients, doctors press FTC to beef up hospital merger scrutiny

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Fed up with FDA, ALS advocates consider a take

FDA weighs limits of animal data in assessing artificial wombs

Lilly’s weekly insulin works as well as daily products, new studies show

focus

leisure time

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Novavax promises a turnaround & Lilly roils the obesity market

Novo Nordisk testing Wegovy against alcohol

What does generative AI mean for health care? We asked experts

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Jerome Adams on the need for new antivirals for Covid

HHS suspends federal funding for EcoHealth Alliance

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The unintended consequences of overturning Roe v. Wade

Wikipedia

Information blocking fines are now fair game in health care

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

PBMs drew scrutiny in House hearing — and so did pharma

People with substance use disorder deserve online privacy

As H5N1 spreads in cows, experts warn against drinking raw milk

The United States must get value

focus

focus

leisure time

hotspot